Peptide-Based Cancer Vaccines: Current Clinical Progress and Combination Strategies | Research

The takeaway

Comprehensive review of peptide-based therapeutic cancer vaccines covering target selection, epitope design, adjuvant optimization, clinical trial results, and combination strategies with other immunotherapies and treatments.

Combinations are key
Peptide vaccines combined with checkpoint inhibitors, chemotherapy, or radiation show superior anti-cancer efficacy — the future is combination immunotherapy

What the researchers found

Peptide cancer vaccines targeting TAAs or TSAs via CD8+/CD4+ epitopes have achieved clinical benefits. Adjuvants and nanomaterials improve immune responses. Combination with other therapies shows superior anti-cancer efficacy. Multiple candidates in advanced clinical development.

Why it matters

Unlike antibody immunotherapies (expensive, IV infusion), peptide vaccines are relatively cheap, easy to manufacture, and can be personalized. Understanding the current clinical landscape helps identify which approaches are most promising.

The numbers in context

Targets: TAAs and TSAs; stimulates CD8+ and CD4+ T cells; adjuvants and nanomaterials reviewed

How the study worked

Comprehensive narrative review of peptide-based therapeutic cancer vaccine development, covering target selection, epitope design/screening, adjuvant optimization, clinical trial results, and combination therapy strategies.

Who was studied

N/A (review of clinical trial data)

What this study cannot tell us

Broad review — individual clinical trial details not deeply analyzed. Response rates for peptide vaccines alone remain modest. Tumor immune escape remains a challenge. Personalized neoantigen vaccines are logistically complex.

How to read the evidence

Not applicable (comprehensive review). Based on published clinical trial data across multiple peptide vaccine programs.

When this study was published

Published 2021. Peptide cancer vaccines continue advancing with mRNA vaccines providing both competition and complementary technology.

The bigger picture

Peptide cancer vaccines are evolving from single-antigen, single-modality approaches to multi-antigen, combination therapies. The field is maturing from "can this work?" to "how do we optimize it for each patient?"

Questions still open

Which peptide vaccine-combination strategy shows the greatest clinical promise?
Can AI-predicted neoantigens replace experimentally identified ones?
Will mRNA vaccines eventually replace peptide vaccines for cancer?

Common questions

What is a peptide cancer vaccine?

A peptide cancer vaccine contains short protein fragments (peptides) from tumor-specific proteins that train the immune system to recognize and attack cancer cells. Unlike preventive vaccines (like HPV), therapeutic cancer vaccines treat existing cancer.

Do peptide cancer vaccines work?

On their own, responses are often modest. But when combined with checkpoint inhibitors (like Keytruda), chemotherapy, or radiation, peptide vaccines have shown significant clinical benefits in multiple trials. The combination approach is where the field is heading.

Read the original research

Peptide-based therapeutic cancer vaccine: Current trends in clinical application.

Cell proliferation, 54(5), e13025

View on PubMed ↗Publisher’s paper ↗

Citation

Liu, Wensi; Tang, Haichao; Li, Luanfeng; Wang, Xiangyi; Yu, Zhaojin; Li, Jianping. (2021). Peptide-based therapeutic cancer vaccine: Current trends in clinical application.. Cell proliferation, 54(5), e13025. https://doi.org/10.1111/cpr.13025